As of November 6, 2026, UroGen Pharma Ltd. is a publicly traded company (Nasdaq: URGN); its largest reported holder is The Toronto-Dominion Bank, with 6.7% on Schedule 13G/A of August 12, 2026, then BlackRock (6.3%). The largest insider holding is Mark Schoenberg, M.D., the chief medical officer, with 59,882 shares (0.12% of shares outstanding), per Form 4 of September 9, 2026 (Schedule 13G/A, August 12, 2026).
Is this your company?
About to sign with, pay or invest in UroGen Pharma Ltd.? See the free Snapshot first.
Free to see. No signup.
Is UroGen Pharma Ltd. a real, registered company?
- UroGen Pharma Ltd. files with the SEC under CIK 1668243 (its SEC filings).
- Its shares are listed under the ticker URGN on Nasdaq (SEC company record).
- Incorporated in L3; business address in Ra'Anana, L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under UroGen Pharma Ltd. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are UroGen Pharma Ltd.'s owners and officers?
UroGen Pharma Ltd.: business address in Ra'Anana, L3; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-08-14)
- : Executive Officer (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Director (Form D, 2023-08-14)
- : Executive Officer (Form D, 2023-08-14)
- : Executive Officer (Form D, 2023-08-14)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 6.3% |
| Schedule 13G/A, 2026-08-12 | The Toronto-Dominion Bank | 6.7% |
| Schedule 13G, 2026-05-15 | The Toronto-Dominion Bank | 5.4% |
| Schedule 13G/A, 2026-05-15 | Paradigm Biocapital Advisors LP | 3.5% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.2% |
| Schedule 13G/A, 2026-02-13 | The Toronto-Dominion Bank | 4.9% |
| Schedule 13G, 2025-11-14 | The Toronto-Dominion Bank | 6.9% |
| Schedule 13G/A, 2025-11-14 | Cowen Financial Products LLC | 0% |
| Schedule 13G/A, 2025-11-14 | Paradigm Biocapital Advisors LP | 9% |
| Schedule 13G/A, 2025-08-14 | Ra Capital Management, L.P. | 0% |
| Schedule 13G, 2025-08-12 | Paradigm Biocapital Advisors LP | 5% |
| Schedule 13G, 2025-08-06 | Morgan Stanley | 5.4% |
Questions about who owns UroGen Pharma Ltd.
Who owns UroGen Pharma Ltd.?
On this page, 3 holders' latest ownership filings report 5% or more of UroGen Pharma Ltd.: The Toronto-Dominion Bank (6.7%, Schedule 13G/A, filed 2026-08-12), Blackrock, Inc. (6.3%, Schedule 13G/A, filed 2026-10-27) and Morgan Stanley (5.4%, Schedule 13G, filed 2025-08-06).
Who are the largest shareholders of UroGen Pharma Ltd.?
By the share each holder's latest filing reports, the largest holders of UroGen Pharma Ltd. on this page are The Toronto-Dominion Bank (6.7%), Blackrock, Inc. (6.3%) and Morgan Stanley (5.4%).
When did The Toronto-Dominion Bank buy into UroGen Pharma Ltd.?
The filings give report dates, not purchase dates. The earliest filing from The Toronto-Dominion Bank on this page is the Schedule 13G, filed 2025-11-14, reporting 6.9%; its latest, Schedule 13G/A filed 2026-08-12, reports 6.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on UroGen Pharma Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on UroGen Pharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on UroGen Pharma Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own UroGen Pharma Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , M.D., the chief medical officer: 59,882 shares (0.12% of shares outstanding) (Form 4, 2026-09-09).
- , the general counsel: 53,141 shares (0.11% of shares outstanding) (Form 4, 2026-09-09).
- , Jr., a director: 8,000 shares (0.02% of shares outstanding) (Form 4, 2026-08-28).
- , the chief financial officer: 4,561 shares (0.01% of shares outstanding) (Form 4, 2026-10-09).
- , a director: 2,000 shares (0.00% of shares outstanding) (Form 4, 2025-12-01).
Shares outstanding: 49,047,823 as of 2026-10-28, from the company's latest SEC cover page.
How much has UroGen Pharma Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-08-14 | $120M | $120M |
Keep reading
More on UroGen Pharma Ltd. and the records around it.
UroGen Pharma Ltd. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Cowen Financial Products LLC also filed stake reports on 1 other company: Stoke Therapeutics Inc (Nov 2025)
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026), Immatics N.V. (May 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/urogen-pharma